Effect of Ulinastatin Preconditioning on Serum IL-6, S100beta Protein Levels and Cerebral Hemodynamic Indices of Premature Infants After Suffocation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046962

Enrollment

Unknown

Registered

2021-06-05

Start date

2019-01-01

Completion date

Unknown

Last updated

2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm birth asphyxia

Interventions

Experimental group:Ulinastatin injection

Control group:Conventional treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Gestational age <= 34 weeks; 2. The diagnosis was in line with the expert consensus standard of neonatal asphyxia formulated by the Neonatal Resuscitation Group of the Chinese Society of Perinatal Medicine in 2016 [1]according to Apgar score and blood gas analysis, they were divided into mild asphyxia and severe asphyxia; 3. Obtain the informed consent of family members.

Exclusion criteria

Exclusion criteria: 1. Premature infant with intrauterine infection; 2. Severe respiratory disease; 3. Pathological jaundice premature infant; 4. There are serious congenital malformations, especially complex congenital heart disease, complex nervous system malformations, and chromosomal or genetic abnormalities.

Design outcomes

Primary

Measure	Time frame
IL-6;S100beta Protein;Cerebral Hemodynamic Indices;	—

Countries

China

Contacts

Public ContactMo Keyuan

People's Hospital of Wuhan University

1095177803@qq.com+86 15172526030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026